SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-21-292221
Filing Date
2021-10-05
Accepted
2021-10-05 17:04:05
Documents
11

Document Format Files

Seq Description Document Type Size
1 S-3 d250700ds3.htm S-3 464870
2 EX-1.2 d250700dex12.htm EX-1.2 216924
3 EX-4.2 d250700dex42.htm EX-4.2 303325
4 EX-4.4 d250700dex44.htm EX-4.4 95657
5 EX-4.5 d250700dex45.htm EX-4.5 97675
6 EX-4.6 d250700dex46.htm EX-4.6 85179
7 EX-5.1 d250700dex51.htm EX-5.1 27111
8 EX-23.1 d250700dex231.htm EX-23.1 1555
9 GRAPHIC g250700g19e51.jpg GRAPHIC 39465
10 GRAPHIC g250700g24e85.jpg GRAPHIC 133632
11 GRAPHIC g250700snap0001.jpg GRAPHIC 3421
  Complete submission text file 0001193125-21-292221.txt   1532751
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-260069 | Film No.: 211307568
SIC: 2836 Biological Products, (No Diagnostic Substances)